Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists.
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Artículo biblioteca |
Language: | eng |
Published: |
Elsevier
2024
|
Subjects: | CANCER DE MAMA, PROLIFERACION CELULAR, METILPIPERAZINA, HISTAMINA, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/18346 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-18346 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-183462024-06-28T05:02:00Z Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer Ospital, Ignacio A. Táquez Delgado, Mónica Alejandra Nicoud, Melisa Beatriz Correa, Michelle F. Borges Fernandes, Gustavo A. Andrade, Isabela W. Lauretta, Paolo Martínez Vivot, Rocío Comba, María Betina Zanardi, María Marta Speisky, Daniela Uriburu, Juan L. Fernandes, João P. S. Medina, Vanina A. CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists. 2024-06-27T12:13:56Z 2024-06-27T12:13:56Z 2024 Artículo Ospital, I. A. Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer [en línea]. Biomedicine & Pharmacotherapy. 2024, 174 ( 116527). doi: 10.1016/j.biopha.2024.116527. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/18346 1950-6007 (online) 0753-3322 (impreso) https://repositorio.uca.edu.ar/handle/123456789/18346 10.1016/j.biopha.2024.116527 eng Acceso abierto http://creativecommons.org/licenses/by-nc/4.0/ application/pdf Elsevier Biomedicine & Pharmacotherapy. 2024, 174 ( 116527) |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng |
topic |
CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA |
spellingShingle |
CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA Ospital, Ignacio A. Táquez Delgado, Mónica Alejandra Nicoud, Melisa Beatriz Correa, Michelle F. Borges Fernandes, Gustavo A. Andrade, Isabela W. Lauretta, Paolo Martínez Vivot, Rocío Comba, María Betina Zanardi, María Marta Speisky, Daniela Uriburu, Juan L. Fernandes, João P. S. Medina, Vanina A. Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
description |
Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast
cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010,
LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in
4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was
assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC
tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human
tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival.
Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023
exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in
4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the
paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing
mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations.
We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic
potential for the novel LINS01 series of H3R antagonists. |
format |
Artículo |
topic_facet |
CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA |
author |
Ospital, Ignacio A. Táquez Delgado, Mónica Alejandra Nicoud, Melisa Beatriz Correa, Michelle F. Borges Fernandes, Gustavo A. Andrade, Isabela W. Lauretta, Paolo Martínez Vivot, Rocío Comba, María Betina Zanardi, María Marta Speisky, Daniela Uriburu, Juan L. Fernandes, João P. S. Medina, Vanina A. |
author_facet |
Ospital, Ignacio A. Táquez Delgado, Mónica Alejandra Nicoud, Melisa Beatriz Correa, Michelle F. Borges Fernandes, Gustavo A. Andrade, Isabela W. Lauretta, Paolo Martínez Vivot, Rocío Comba, María Betina Zanardi, María Marta Speisky, Daniela Uriburu, Juan L. Fernandes, João P. S. Medina, Vanina A. |
author_sort |
Ospital, Ignacio A. |
title |
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
title_short |
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
title_full |
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
title_fullStr |
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
title_full_unstemmed |
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
title_sort |
therapeutic potential of lins01 histamine h3 receptor antagonists as antineoplastic agents for triple negative breast cancer |
publisher |
Elsevier |
publishDate |
2024 |
url |
https://repositorio.uca.edu.ar/handle/123456789/18346 |
work_keys_str_mv |
AT ospitalignacioa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT taquezdelgadomonicaalejandra therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT nicoudmelisabeatriz therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT correamichellef therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT borgesfernandesgustavoa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT andradeisabelaw therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT laurettapaolo therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT martinezvivotrocio therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT combamariabetina therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT zanardimariamarta therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT speiskydaniela therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT uriburujuanl therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT fernandesjoaops therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer AT medinavaninaa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer |
_version_ |
1806028968457928704 |